Ionis Pharmaceuticals, Inc. (IONS)

NASDAQ: IONS · Real-Time Price · USD

75.56

-0.22 (-0.29%)

At close: May 22, 2026, 4:00 PM EDT

76.06

+0.50 (0.66%)

After-hours: May 22, 2026, 5:31 PM EDT

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
TRYNGOLZA Revenue	128.30M	107.50M	-
TRYNGOLZA Revenue Growth	19.35%	-	-
DAWNZERA Revenue	-	7.80M	-
Total Product Revenue	152.00M	115.30M	-
Total Product Revenue Growth	31.83%	-	-
SPINRAZA Royalties Revenue	208.00M	212.30M	216.10M
SPINRAZA Royalties Revenue Growth	-2.02%	-1.76%	-10.11%
WAINUA Royalties Revenue	50.40M	49.10M	20.20M
WAINUA Royalties Revenue Growth	2.65%	143.07%	-
TEGSEDI and WAYLIVRA Revenue	32.10M	35.00M	34.20M
TEGSEDI and WAYLIVRA Revenue Growth	-8.29%	2.34%	-2.01%
Commercial Licensing and Other Royalty Revenue	18.60M	24.10M	22.60M
Commercial Licensing and Other Royalty Revenue Growth	-22.82%	6.64%	-32.13%
Total Commercial Revenue	467.40M	435.80M	293.10M
Total Commercial Revenue Growth	7.25%	48.69%	-5.02%
Amortization from Upfront Payments Revenue	-	-	131.40M
Amortization from Upfront Payments Revenue Growth	-	-	4.87%
Milestone Payments Revenue	-	-	106.40M
Milestone Payments Revenue Growth	-	-	5.87%
R&D License Fees Revenue	-	-	71.30M
R&D License Fees Revenue Growth	-	-	-38.95%
Other R&D Services Revenue	-	-	23.50M
Other R&D Services Revenue Growth	-	-	135.00%
Collaborative Agreement Revenue	541.50M	465.80M	332.60M
Collaborative Agreement Revenue Growth	16.25%	40.05%	-5.67%
Eplontersen Joint Development Revenue	49.30M	42.10M	79.40M
Eplontersen Joint Development Revenue Growth	17.10%	-46.98%	-37.18%
Total R&D Revenue	590.80M	507.90M	412.00M
Total R&D Revenue Growth	16.32%	23.28%	-13.99%
Revenue (Other)	-793.21M	-672.29M	-432.16M
Revenue (Total)	1.06B	943.71M	705.14M
Revenue (Total) Growth	12.13%	33.83%	-10.47%

Updated Apr 29, 2026. Data Source: Fiscal.ai.